Kazia Therapeutics (KZIA) Cash & Equivalents (2017 - 2025)

Kazia Therapeutics (KZIA) has disclosed Cash & Equivalents for 6 consecutive years, with $2.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash & Equivalents rose 154.82% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Jun 2025, up 154.82%, and an annual FY2025 reading of $2.8 million, up 159.13% over the prior year.
  • Cash & Equivalents was $2.8 million for Q2 2025 at Kazia Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $5.3 million in Q2 2022 and bottomed at $1.1 million in Q2 2024.
  • Average Cash & Equivalents over 4 years is $3.2 million, with a median of $3.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 68.83% in 2024, then surged 154.82% in 2025.
  • Year by year, Cash & Equivalents stood at $5.3 million in 2022, then crashed by 33.56% to $3.5 million in 2023, then crashed by 68.83% to $1.1 million in 2024, then soared by 154.82% to $2.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for KZIA at $2.8 million in Q2 2025, $1.1 million in Q2 2024, and $3.5 million in Q2 2023.